Skip to main content
Premium Trial:

Request an Annual Quote

Servier Licenses Cellectis Cell Lines

NEW YORK (GenomeWeb News) – French drug firm Servier has licensed non-exclusive rights to use Cellectis' π10 modified cell lines for high-throughput screening efforts.

The new agreement follows a recently concluded research pact between the firms that began in 2007.

"The cells, gene insertion templates and meganuclease used by Servier are now available as a commercial kit, which provides a reliable, easy-to-use method of creating cell lines specific to drug targets of interest," said Marc Le Bozec, CEO and CFO of Cellectis BioResearch, the subsidiary of Cellectis that markets the kits.

Financial and other terms were not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.